You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of the first thermolytic to suppress shivering and seizure

    SBC: Be Cool Pharmaceutics LLC            Topic: NHLBI

    Summary The temperature management market is expected to reach $billion byyet no pharmaceutical has yet been developed specifically for this marketAadenosineA ARagonists are well known to attenuate seizure and protect the brain from injurybut development of these drugs has been limited by side effects including hypothermiabradycardia and hypotensionInspired by our discoveries thatN cyclohexyl aden ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Science Take-Out Kits for Environmental Health Education

    SBC: Science Take-Out, LLC            Topic: NIEHS

    ABSTRACT Nearlypercent of death and diseaseworldwideis linked to environmental factorsWHOthereforeit is critical that the general public has a basic understanding of how the environment affects their health and how they might protect themselves against environmental exposuresUnfortunatelyenvironmental health is typically covered minimallyif at allin secondary school classroomsMartinaand there are ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. In Vivo Editing for Hemophilia Gene Therapy

    SBC: GENVEC, INC.            Topic: 100

    Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an adeno associated vector AAV In spite of this watershed event in the history of the gene therapy field there presently exist barriers to the fullest implementation of hemophilia gene therapy The li ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease Using Skin Elasticity as a Biomarker

    SBC: Microelastic Ultrasound Systems, Inc.            Topic: 102

    Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease using Skin Elasticity as a Biomarker ABSTRACT Sclerotic chronic graft versus host disease cGVHD develops in of allogenic Human Stem Cell Transplant HCT recipients and is associated with significant morbidity and mortality GVHD is treated with immunosuppression which puts patients at severe risk of infection ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. A novel product for tendinopathy treatment

    SBC: NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC.            Topic: NIA

    Project Summary This study aims to prove the concept and feasibility that TendonCure extracellular vesicles that contain signaling molecules i e exosomes secreted by mesenchymal stem cells i e tendon stem progenitor cells TSPCs or adipose derived stem cells ADSCs from individual patients donors cultured on a novel scaffold exert therapeutic efficacy on tendinopathy when injected into ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Creation of animal models of mitochondrial DNA disease for translational research applications

    SBC: Enzerna Biosciences LLC            Topic: 400

    Mitochondria are the principal generators of cellular ATP by oxidative phosphorylation which links electron transport via Complexes I through IV to production of ATP via ATP synthase Over pathogenic human mitochondrial DNA mtDNA mutations associated with diseases ranging from cardiomyopathy to juvenile blindness have been identified Collectively millions are affected by mtDNA disease fo ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Structure based optimization of a novel pharmacological chaperone therapy for MPSIIIC

    SBC: Phoenix Nest Inc.            Topic: NICHD

    PROJECT SUMMARY Lysosomal storage diseases LSD are rare inherited metabolic disorders caused by defects in the cellular catabolic system Mucopolysaccharidosis Type IIIC MPS IIIC or Sanfilippo disease type C is one such LSD that is caused by deficiency of the enzyme heparan sulfate acetyl CoA glucosaminide N acetyltransferase HGSNAT essential for degradation of heparan sulfate a repeati ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A Systematic Medical Approach to Reward Transformation SMART for Brain Health in Opioid Use Disorder

    SBC: Versa Integrated Solutions, Inc.            Topic: 102

    Summary In recent years opioid use disorder OUD and deaths due to opiate overdose e g with heroin fentanyl oxycodone in suburban and rural non minority groups has created an urgency for approaches to stem this epidemic but the rise in OUD and opiate overdose deaths has occurred in inner cities at similar rates Heroin misuse and addiction are persistent problems in African American commu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a POEGMA Aptamer rapid onset anticoagulant that eliminates antigenicity to anti PEG antibodies

    SBC: Gateway Bio, Inc.            Topic: NHLBI

    ABSTRACT The objective of this STTR proposal is to reformulate a promising PEG aptamer rapid onset anticoagulant ROA by applying a novel PEG like POEGMA polymer brush technology capable of eliminating anti PEG antigenicity The importance of this proposal is highlighted by the early termination of a recent Phase III clinical trial of the original PEG aptamer conjugate in which severe allergic ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government